Clinical Research Directory

Inclusion Criteria: 1. Male and female\* patients ≥ 18 of age 2. Screening eGFR ≥ 25 and ≤ 90 mL/min/1.73 m2 if age ≥ 18 and ≤50 years or Screening eGFR ≥ 25 and ≤ 65 mL/min/1.73 m2 if age \> 50 years 3. ADPKD diagnosed by unified criteria (combination of family history, ultrasound, MRI/CT, genotyping as needed) 4. Mayo Class I C, D, E 5. Patients with and without tolvaptan use will be included. Patients with tolvaptan use will be included if tolvaptan has been taken for ≥ 3 months at study entry. 6. Willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures 7. Evidence of signed written informed consent. Exclusion criteria: 1. Kidney or any other solid organ transplant recipient 2. Currently receiving SGLT2-inhibitor 3. Concomitant treatment with steroids or any other immunosuppressive agent 4. Hypersensitivity to the active principle (Empagliflozin) or any of the excipients (e.g. lactose) 5. Ketoacidosis (laboratory based) in the past 5 years 6. Type 1 diabetes mellitus 7. Ongoing urinary tract- or genital infections 8. Inability to fully understand the possible risks and benefits related to study participation 9. Inability to undergo MRI exam (e.g. implanted medical devices) 10. Women who are pregnant or breastfeeding 11. Unwilling to practice acceptable methods of birth control during study participation 12. Participation in another clinical trial (other investigational drugs or devices at the time of enrolment or within 30 days prior to enrolment)